Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 12 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| ARQULE INC | 11,324,073 | reported | 17 Sept 2009 | tx 12+1,780,396−3,680,000 |
| Celera CORP | 10,326,017 | reported | 14 Apr 2011 | tx 9+215,000 |
| COMBINATORX, INC | 8,412,999 | reported | 26 Nov 2008 | tx 9+101,700 |
| AVIGEN INC \DE | 8,149,515 | reported | 12 Nov 2008 | tx 12+355,900 |
| ADOLOR CORP | 6,214,551 | reported | 31 Oct 2008 | tx 1+1,000 |
| SUPERGEN INC | 5,753,399 | reported | 09 May 2008 | tx 14−119,501 |
| SGX PHARMACEUTICALS, INC. | 5,507,674 | reported | 11 Jul 2008 | tx 12+1,298,100 |
| DYNAVAX TECHNOLOGIES CORP | 5,492,957 | reported | 06 Aug 2009 | tx 6−399,500 |
| NEUROCRINE BIOSCIENCES INC | 5,041,447 | reported | 12 Apr 2010 | tx 19+140,900−303,000 |
| Oncothyreon Inc. | 4,808,531 | reported | 01 Nov 2013 | tx 8+343,467 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 24 Jan 2025 | SALE | XOMA Royalty Corp | 75,287 | 26.10 USD | |
| 24 Jan 2025 | SALE | XOMA Royalty Corp | 85,776 | 26.10 USD | |
| 24 Jan 2025 | SALE | XOMA Royalty Corp | 149,975 | 26.10 USD | |
| 24 Jan 2025 | SALE | XOMA Royalty Corp | 339,679 | 26.10 USD | |
| 18 Jun 2024 | GRANT_AWARD | Kymera Therapeutics, Inc. | 16,000 | 0.00 USD | deriv |
| 26 Jun 2023 | TENDER | CELL THERAPEUTICS INC | 3,989,130 | 9.10 USD | |
| 26 Jun 2023 | TENDER | CELL THERAPEUTICS INC | 2,595,239 | 9.10 USD | |
| 26 Jun 2023 | TENDER | CELL THERAPEUTICS INC | 43,139 | 9.10 USD | |
| 26 Jun 2023 | TENDER | CELL THERAPEUTICS INC | 1,526,147 | 9.10 USD | |
| 26 Jun 2023 | TENDER | CELL THERAPEUTICS INC | 702,505 | 9.10 USD | |
| 26 Jun 2023 | TENDER | CELL THERAPEUTICS INC | 17 | — | deriv |
| 26 Jun 2023 | OTHER | CELL THERAPEUTICS INC | 80,000 | — | deriv |
| 26 Jun 2023 | OTHER | CELL THERAPEUTICS INC | 80,000 | — | deriv |
| 26 Jun 2023 | OTHER | CELL THERAPEUTICS INC | 80,000 | — | deriv |
| 26 Jun 2023 | OTHER | CELL THERAPEUTICS INC | 50,000 | — | deriv |
| 26 Jun 2023 | TENDER | CELL THERAPEUTICS INC | 1,594 | — | deriv |
| 26 Jun 2023 | TENDER | CELL THERAPEUTICS INC | 1,250 | — | deriv |
| 26 Jun 2023 | TENDER | CELL THERAPEUTICS INC | 191 | — | deriv |
| 26 Jun 2023 | TENDER | CELL THERAPEUTICS INC | 12 | — | deriv |
| 26 Jun 2023 | TENDER | CELL THERAPEUTICS INC | 344 | — | deriv |
| 26 Jun 2023 | TENDER | CELL THERAPEUTICS INC | 239 | — | deriv |
| 26 Jun 2023 | OTHER | CELL THERAPEUTICS INC | 120,000 | — | deriv |
| 26 Jun 2023 | OTHER | CELL THERAPEUTICS INC | 60,000 | — | deriv |
| 16 Jun 2023 | GRANT_AWARD | Olema Pharmaceuticals, Inc. | 21,520 | 0.00 USD | deriv |
| 10 May 2023 | OTHER | Structure Therapeutics Inc. | 462,605 | — |
3 purchases reported after at least 12 months of silence — most recent on 19 Nov 2018.